Why the study?
Residual congestion after therapy for acute decompensated heart failure is common and linked to worse outcomes, but standardized decongestion end point definitions are lacking.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Does not support immediate clinical use; leaves open whether the proposed scheme improves trial consistency in acute decompensated heart failure.
Congestion is the most common manifestation of acute decompensated heart failure (ADHF). Residual congestion despite initial medical therapy is common and is recognized to be associated with worse outcomes; however, there are currently no standardized definition regarding decongestion end point. In the second part of this 2-part review, we provide a critical appraisal of decongestion definitions previously used in ADHF studies, review alternative metrics to define severity of volume overload, and propose a more granular 4-class congestion grading scheme and decongestion end point definitions that could potentially be included in future ADHF trials and consensus definitions.
No takes yet. Share an insight, caveat, or question.
Georges et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: